Therapeutic effects and safety of Chinese herbal formula Tongxie Yaofang versus placebo for diarrhea-predominant irritable bowel syndrome

2021 ◽  
Author(s):  
Jian-ping Liu ◽  
Hong-Jie Cheng
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Effects ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

scholarly journals JCM-16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS-Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Hong-Yan Qin ◽  
Hai-Tao Xiao ◽  
Fung-Ping Leung ◽  
Zhi-Jun Yang ◽  
Justin C. Y. Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Analgesic Effect ◽  
Tryptophan Hydroxylase ◽  
Herbal Formula ◽  
Mechanical Stimuli ◽  
Visceral Hyperalgesia ◽  
Cell Hyperplasia ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

The present study aimed to investigate the analgesic effect of JCM-16021, a revised traditional Chinese herbal formula, on postinflammatory irritable bowel syndrome (PI-IBS) in rats. The trinitrobenzene sulfonic (TNBS) acid-induced PI-IBS model rats were orally administrated with different doses of JCM-16021 (1.2, 2.4, and 4.8 g/kg/d) for 14 consecutive days. The results showed that JCM-16021 treatment dose-dependently attenuated visceral hyperalgesia in PI-IBS rats. Further, the colonic enterochromaffin (EC) cell number, serotonin (5-HT) content, tryptophan hydroxylase expression, and mechanical-stimuli-induced 5-HT release were significantly ameliorated. Moreover, the decreased levels of mucosal cytokines in PI-IBS, especially the helper T-cell type 1- (Th1-) related cytokine TNF-α, were also elevated after JCM-16021 treatment. These data demonstrate that the analgesic effect of JCM-16021 on TNBS-induced PI-IBS rats may be medicated via reducing colonic EC cell hyperplasia and 5-HT availability.

scholarly journals The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiaohui Guo ◽  
Meiling Xuan ◽  
Huan Zheng ◽  
Shumin Qin ◽  
Haomeng Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Outcome Measures ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Life Questionnaire ◽  
Herbal Formula ◽  
Efficacy And Safety ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

Abstract Background Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evaluate the efficacy and safety of HXZQ for IBS-D patients. Methods This is a double-blind, randomized, placebo-controlled trial. The 212 eligible patients with IBS-D will be randomly assigned to receive either HXZQ oral liquid or a placebo, at a 1:1 ratio, for 4 weeks with a 4-week follow-up period. Adequate relief will be the primary outcome measures. IBS symptom severity score, IBS quality-of-life questionnaire, EQ-5D-5L, and Chinese medicine symptom questionnaire will be the secondary outcome measures. Discussion This trial aims to demonstrate the efficacy and safety of HXZQ for IBS-D, which is expected to be an effective IBS-D treatment. Trial registration The trial was registered with the Chinese Clinical Trial Registry, ChiCTR1900026837. Registered on 24 October 2019.

scholarly journals Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Qian Huang ◽  
Xiaohui Guo ◽  
Meiling Xuan ◽  
Wenwei Ouyang ◽  
Zehuai Wen
Keyword(s):  
Atopic Dermatitis ◽  
Irritable Bowel Syndrome ◽  
Observational Study ◽  
Severity Index ◽  
Protocol Design ◽  
Herbal Formula ◽  
High Quality ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

Introduction. Atopic dermatitis (AD) and diarrhea-predominant irritable bowel syndrome (IBS-D) are two recurrent diseases with limited effective treatments. In Chinese Medicine (CM) theory, they may share dampness pattern as the same dominant pathogenesis at a certain stage and, thus, can be treated with the same method. While Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been reported as an effective dampness-resolving therapy for both AD and IBS-D, further high-quality clinical studies are still needed. In addition, HXZQ lacks accurate clinical positioning based on CM patterns. Therefore, we utilize a master protocol design to evaluate HXZQ for dampness pattern simultaneously in AD and IBS-D, with the aim of identifying the pattern-defined population of HXZQ. Methods and Analysis. This master protocol design includes two randomized controlled trials (RCTs) and a real-world observational study. Based on two registry cohorts of AD and IBS-D, patients with dampness pattern will be enrolled in the RCTs to receive either HXZQ oral liquid or a placebo for 4 weeks and then will be followed up for another 4 weeks, while patients with nondampness pattern will constitute the observational study and experience a 12-week follow-up. A total of 678 AD patients and 322 IBS-D patients will be recruited from 14 hospitals in China over a 3-year period. The eczema area and severity index (EASI) and the proportion of responders for adequate relief (AR) are the primary outcomes in AD and IBS-D, respectively. Analysis will be undertaken separately in each substudy, and then an overall analysis combining multiple subgroups will be performed to comprehensively investigate the effect of HXZQ. Discussion. This study will provide high-quality efficacy evidence of HXZQ for AD and IBS-D patients and give an example of postmarketing evaluation for CM products under the pattern dominating different disease research model. The study is registered with ChiCTR1900026700 and ChiCTR1900026837.

Effectiveness of the Chinese Herbal Formula TongXieYaoFang for Irritable Bowel Syndrome: A Systematic Review

2006 ◽  
Vol 12 (4) ◽  
pp. 401-407 ◽  
Author(s):  
Zhaoxiang Bian ◽  
Taixiang Wu ◽  
Liang Liu ◽  
Jiangxia Miao ◽  
Honfat Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Irritable Bowel Syndrome ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

scholarly journals Xiaoyao-san, a traditional Chinese herbal formula, for the treatment of irritable bowel syndrome

Medicine ◽  
2021 ◽  
Vol 100 (10) ◽  
pp. e24019
Author(s):  
JiHo Lee ◽  
Won-Suk Sung ◽  
Eun-Jung Kim ◽  
Young Woo Kim
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

scholarly journals The Chinese Herbal Formula PAPZ Ameliorates Behavioral Abnormalities in Depressive Mice

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 859 ◽  
Author(s):  
Huiling Chen ◽  
Qing Huang ◽  
Shunjia Zhang ◽  
Kaiqiang Hu ◽  
Wenxiang Xiong ◽  
...  
Keyword(s):  
Protein Expression ◽  
Therapeutic Effects ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Hippocampal Tissue ◽  
Behavioral Abnormalities ◽  
Antidepressant Effects ◽  
Polygala Tenuifolia ◽  
History Of

Major depressive disorder (MDD) is a chronic mental disorder characterized by mixed symptoms and complex pathogenesis. With long history of practical application, traditional Chinese medicine (TCM) offers many herbs for the treatment and rehabilitation of chronic disease. In this study, we developed a modified Chinese herbal formula using Panax ginseng, Angelica Sinensis, Polygala tenuifolia Willd, and Ziziphi spinosae Semen (PAPZ), based on an ancient TCM prescription. The antidepressant effects of PAPZ were investigated with a corticosterone (CORT) model of depression in mice. Our results showed that administration of PAPZ ameliorated depression-like phenotypes in the CORT model. An anatomic study showed that chronic PAPZ administration upregulated the protein expression of brain-derived neurotrophic factor (BDNF) in hippocampal tissue. The enzyme activity of superoxide dismutase was enhanced in hippocampal tissue, in line with a decreased malondialdehyde level. Taken together, these findings suggested that PAPZ has therapeutic effects in a mice depression model through increasing protein expression of BDNF and improving the anti-oxidation ability of the brain.

scholarly journals Therapeutic Effects of Chinese Herbal Formula (PTQX) on NC/Nga Mice with Atopic Dermatitis-Like Skin Lesions

2019 ◽  
Vol 2019 ◽  
pp. 1-13
Author(s):  
Fenggen Yan ◽  
Jing Zhang ◽  
Xiong Li ◽  
Xiumei Mo ◽  
Junfeng Liu ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Mast Cells ◽  
Lymph Nodes ◽  
Immunoglobulin E ◽  
Skin Lesions ◽  
Therapeutic Effects ◽  
Herbal Formula ◽  
Dorsal Skin ◽  
Chinese Herbal Formula ◽  
Chinese Herbal

Atopic dermatitis (AD), also known as atopic eczema, is a chronic pruritic inflammatory skin disease. The available systemic therapies for atopic dermatitis are inadequate. Objective. This study aimed to evaluate the effects of the Chinese herbal formula Pei Tu Qing Xin (PTQX) on dermatitis severity and ear swelling, immunomodulation, and the infiltration of mast cells in a mouse model of 1-chloro-2,4-dinitrobenzene- (DNCB-) induced AD. Methods. AD-like symptoms were induced by DNCB in NC/Nga mice. Skin lesions, dermatitis, ear swelling, and scratching behaviour were evaluated. Changes in the T-helper type 1 (Th1), Th2, Th17, and regulatory T (Treg) subtypes and immunoregulation in the spleen and lymph nodes were detected by flow cytometry. Results. Histopathological and immunohistochemical analyses demonstrated that PTQX decreased the DNCB-mediated induction of mast cells and infiltration of inflammatory cells in the ear and dorsal skin. PTQX also reduced the DNCB-induced increase in the serum immunoglobulin E level, pruritus, and dermatitis (red, flaky areas) on the dorsal skin. Furthermore, PTQX regulated the balance between the populations of Th1, Th2, Th17, and Treg cells (particularly the latter two) in the lymph nodes. Conclusions. Our results suggest that the Chinese herbal formula PTQX can alleviate symptoms of AD, such as epithelial damage, redness, swelling, and pruritus, and potentially be used to treat this condition.

scholarly journals In VivoStudy on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Chun-Hay Ko ◽  
Wing-Sum Siu ◽  
Hing-Lok Wong ◽  
Si Gao ◽  
Wai-Ting Shum ◽  
...  
Keyword(s):  
Synergistic Effects ◽  
Ovariectomized Rats ◽  
Therapeutic Effects ◽  
Herbal Formula ◽  
Mineral Density ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Pharmacological Interactions ◽  
Long Term Treatment ◽  
Antiresorptive Drugs

Antiresorptive drugs, alendronate and raloxifene, are effective in lowering bone mineral density (BMD) loss in postmenopausal women. However, long-term treatment may be associated with serious side effects. Our research group has recently discovered that a Chinese herbal formula, ELP, could significantly reduce BMD loss in animal and human studies. Therefore, the present study aimed to investigate the potential synergistic bone-protective effects of different herb-drug combinations using ovariectomized rats. To assess the efficacy of different combinations, the total BMD was monitored biweekly in the 8-week course of daily oral treatment. Bone microarchitecture, bone strength, and deoxypyridinoline level were also determined after 8 weeks. From our results, coadministration of ELP and raloxifene increased the total tibial BMD by 5.26% (2.5 mg/kg/day of raloxifene;P=0.014) and 5.94% (0.25 mg/kg/day of raloxifene;P=0.026) when compared with the respective dosage groups with raloxifene alone. Similar synergistic effects were also observed in BMD increase at distal femur (0.25 mg/kg/day;P=0.001) and reduction in urinary deoxypyridinoline crosslink excretion (2.5 and 0.25 mg/kg/day; bothP=0.02). However, such interactions could not be observed in all alendronate-treated groups. Our data provide first evidence that ELP could synergistically enhance the therapeutic effects of raloxifene, so that the clinical dosage of raloxifene could be reduced.

Sign in / Sign up

Export Citation Format

Share Document